NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 40 filers reported holding NEUROCRINE BIOSCIENCES INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,587 | -100.0% | 1,000 | -100.0% | 0.00% | -100.0% |
| Q4 2020 | $64,681,000 | -0.6% | 46,390,000 | 0.0% | 0.06% | -15.8% |
| Q3 2020 | $65,053,000 | -38.2% | 46,390,000 | -23.2% | 0.08% | -37.7% |
| Q2 2020 | $105,347,000 | +23.9% | 60,425,000 | -5.5% | 0.12% | +7.0% |
| Q1 2020 | $85,025,000 | -24.2% | 63,975,000 | -11.4% | 0.11% | +11.8% |
| Q4 2019 | $112,242,000 | +22.7% | 72,175,000 | +8.4% | 0.10% | +13.3% |
| Q3 2019 | $91,443,000 | +28.3% | 66,555,000 | +23.5% | 0.09% | +36.4% |
| Q2 2019 | $71,274,000 | -12.7% | 53,905,000 | -12.3% | 0.07% | -18.5% |
| Q1 2019 | $81,630,000 | +5.0% | 61,500,000 | -5.6% | 0.08% | -4.7% |
| Q4 2018 | $77,766,000 | -39.9% | 65,145,000 | -13.5% | 0.08% | -27.4% |
| Q3 2018 | $129,343,000 | +6.0% | 75,285,000 | -10.2% | 0.12% | -0.8% |
| Q2 2018 | $122,059,000 | – | 83,875,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SSI INVESTMENT MANAGEMENT LLC | 7,440,000 | $10,058,000 | 0.84% |
| SHENKMAN CAPITAL MANAGEMENT INC | 4,121,000 | $5,579,000 | 0.72% |
| Baker Brothers Advisors | 53,270,000 | $71,994,000 | 0.46% |
| LINDEN ADVISORS LP | 11,675,000 | $15,814,000 | 0.36% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 11,558,000 | $15,650,000 | 0.34% |
| AQR Arbitrage LLC | 20,000,000 | $27,077,000 | 0.34% |
| CSS LLC/IL | 3,455,000 | $4,675,000 | 0.28% |
| RWC Asset Management LLP | 4,000,000 | $5,396,000 | 0.25% |
| MACKAY SHIELDS LLC | 21,460,000 | $29,043,000 | 0.21% |
| Calamos Advisors LLC | 24,105,000 | $32,660,000 | 0.20% |